NL-OMON21705招募中不适用
A single-blind, double dummy, randomized, multi-dose, two sequence, crossover, study to investigate the effects of Renin Inhibitor (aliskiren 300 mg) on Albuminuria in non-diabetic nephropathy patients treated with ramipril 10 mg and Volume intervention (ARIA).
MCG, Novartis0 个研究点目标入组 32 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 32
研究概览
简要总结
/A
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Male and female outpatients at least 18 years old;
- •2. Non-diabetic renal disease as established by history, urine analysis, serum biochemistry tests and/or renal biopsy with residual albuminuria by UAER of >300 mg/24 hrs from 24 hour urine collection during conventional RAAS-blockade of at least 8 weeks of ACEinhibition or ARB treatment at the maximum recommended dose;
排除标准
- •1. Previously treated (within 3 months of screening) with aliskiren or a combination of
- •aliskiren and ramipril;
研究者
相似试验
已完成
2 期
A single-blind, double dummy, randomized, multi-dose, two sequence, crossover, study to investigate the effects of Renin Inhibitor (aliskiren 300 mg) on Albuminuria in nondiabetic nephropathy patients treated with ramipril 10 mg and Volume intervention (CSPP100A2260, ARIA study)nondiabetic nephropathy10029149NL-OMON36542ovartis32
进行中（未招募）
不适用
A single-blind, double dummy, randomized, multi-dose, two sequence, crossover, study to investigate the Added effects of Renin Inhibitor (aliskiren 300 mg) on Albuminuria in non-diabetic nephropathy patients treated with ramipril 10 mg and Volume intervention (ARIA)EUCTR2009-012196-10-NLovartis Pharma Services AG32
进行中（未招募）
不适用
A randomized, double-blind, double-dummy, active (formoterol 12 µg b.i.d) and placebo controlled, multi-center, 5 period crossover, dose-ranging study to assess the bronchodilatory efficacy and safety of single doses of indacaterol 150 µg, 300 µg and 600 µg delivered via single dose dry powder inhaler (SDDPI) vs. placebo in patients with moderate to severe chronic obstructive pulmonary disease (COPD).Chronic obstructive pulmonary diseaseMedDRA version: 8.1Level: LLTClassification code 10009033Term: Chronic obstructive pulmonary diseaseEUCTR2006-004069-33-BEovartisPharma Services AG60
进行中（未招募）
不适用
Comparing the efficacy of Bricanyl M2 and Bricanyl M3 at 0.5 and 1.5 mg dose levels, to allow for a switch from Bricanyl Turbuhaler M2 to Bricanyl Turbuhaler M3AsthmaEUCTR2014-001457-16-SEAstraZeneca AB60
已完成
3 期
A randomised, double-blind, double-dummy, multi-site, phase III, single dose, 4-way cross-over pharmacodynamic study evaluating the efficacy of Bricanyl Turbuhaler M3 compared to Bricanyl Turbuhaler M2 by studying the protective effect on methacholine induced bronchoconstriction in patients with stable, mild to moderate asthmaAsthma10006436NL-OMON42299Astra Zeneca10